ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 97 filers reported holding ONCOCYTE CORP in Q3 2021. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $39,000 | -48.0% | 25,949 | -25.0% | 0.00% | – |
| Q4 2021 | $75,000 | -35.3% | 34,606 | +6.4% | 0.00% | – |
| Q3 2021 | $116,000 | -79.4% | 32,513 | -66.8% | 0.00% | -100.0% |
| Q2 2021 | $562,000 | +0.7% | 97,877 | -9.0% | 0.00% | 0.0% |
| Q1 2021 | $558,000 | +144.7% | 107,507 | +12.9% | 0.00% | – |
| Q4 2020 | $228,000 | +72.7% | 95,193 | 0.0% | 0.00% | – |
| Q3 2020 | $132,000 | +5.6% | 95,193 | +45.9% | 0.00% | – |
| Q2 2020 | $125,000 | +52.4% | 65,227 | +94.8% | 0.00% | – |
| Q1 2020 | $82,000 | +10.8% | 33,478 | +1.2% | 0.00% | – |
| Q4 2019 | $74,000 | +7.2% | 33,095 | 0.0% | 0.00% | – |
| Q3 2019 | $69,000 | -15.9% | 33,095 | 0.0% | 0.00% | – |
| Q2 2019 | $82,000 | +530.8% | 33,095 | +417.1% | 0.00% | – |
| Q1 2018 | $13,000 | -56.7% | 6,400 | 0.0% | 0.00% | – |
| Q4 2017 | $30,000 | -37.5% | 6,400 | 0.0% | 0.00% | – |
| Q3 2017 | $48,000 | +45.5% | 6,400 | 0.0% | 0.00% | – |
| Q2 2017 | $33,000 | +17.9% | 6,400 | +6.6% | 0.00% | – |
| Q1 2016 | $28,000 | – | 6,003 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 23,353,697 | $17,048,000 | 1.30% |
| AWM Investment Company, Inc. | 7,746,557 | $5,655,000 | 0.86% |
| PURA VIDA INVESTMENTS, LLC | 18,056,274 | $13,181,000 | 0.76% |
| Defender Capital, LLC. | 2,551,980 | $1,883,000 | 0.74% |
| Penbrook Management LLC | 563,350 | $411,000 | 0.35% |
| ACT CAPITAL MANAGEMENT, LLC | 330,000 | $241,000 | 0.33% |
| CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $55,000 | 0.04% |
| Fort Sheridan Advisors LLC | 135,000 | $99,000 | 0.03% |
| Orbimed Advisors | 1,882,768 | $1,374,000 | 0.03% |
| WEALTH EFFECTS LLC | 51,000 | $37,000 | 0.02% |